What is the recommended eradication regimen for Pseudomonas aeruginosa in a patient with bronchiectasis?

Pseudomonas Eradication Treatment in Bronchiectasis

For new isolation of Pseudomonas aeruginosa in bronchiectasis, offer eradication therapy with first-line treatment of oral ciprofloxacin 500-750 mg twice daily for 2 weeks, or second-line treatment with IV anti-pseudomonal beta-lactam ± IV aminoglycoside for 2 weeks followed by 3 months of nebulized colistin, gentamicin, or tobramycin. 1

Treatment Algorithm

First-Line Eradication Regimen

• Oral ciprofloxacin 500-750 mg twice daily for 2 weeks 1
• This is the preferred initial approach for most patients with new P. aeruginosa isolation

Second-Line Eradication Regimen

When first-line therapy fails or in patients with clinical deterioration:

• IV anti-pseudomonal beta-lactam (e.g., ceftazidime) ± IV aminoglycoside (e.g., tobramycin) for 2 weeks
• Followed by nebulized antibiotics for 3 months:
  • Colistin (first choice) 1
  • Gentamicin (alternative) 1
  • Tobramycin (alternative) 1

The most recent 2025 ERS guideline 2 provides a conditional recommendation for eradication treatment, acknowledging very low certainty of evidence but emphasizing the overwhelming evidence that chronic P. aeruginosa infection leads to increased mortality, exacerbations, and worse quality of life.

Expected Outcomes

Eradication success rate is approximately 40% at 12 months 2, 3. The meta-analysis by Chalmers et al. 3 found that combined systemic and inhaled antibiotic treatment achieved higher eradication rates (48%) compared to systemic antibiotics alone (27%), supporting the second-line regimen approach.

The landmark RCT by Orriols et al. 4 demonstrated that 3 months of nebulized tobramycin following IV antibiotics resulted in:

• 54.5% remaining P. aeruginosa-free versus 29.4% with placebo
• Significantly reduced exacerbations (p=0.044)
• Fewer hospital admissions (p=0.037) and days hospitalized (p=0.034)

Clinical Context and Nuances

When to Offer Eradication

The 2025 ERS guideline 2 defines "new isolation" as either:

• First-ever P. aeruginosa detection
• Re-isolation after prolonged period of negative cultures (intermittent positivity)

Patient Discussion Points

Both the 2025 ERS 2 and 2019 BTS 1 guidelines emphasize discussing with patients:

• The likelihood of achieving sustained eradication (~40%)
• Risk of developing chronic infection if eradication not attempted
• Treatment burden, particularly with inhaled antibiotics
• Risk of adverse events including antimicrobial resistance

The 2019 BTS guideline 1 specifically notes that clinical observation (without eradication) is an acceptable alternative in stable bronchiectasis after shared decision-making, though eradication should be offered when there is clinical deterioration.

Monitoring Protocol

Send sputum for culture and sensitivity:

• Immediately before starting eradication therapy
• At each clinical attendance following treatment 1
• This determines whether eradication was successful

Important Caveats

Bronchospasm Risk

The Orriols study 4 noted remarkable bronchospasm with nebulized tobramycin. Consider pre-treatment with bronchodilators and monitor closely during initial doses.

Spontaneous Clearance

The 2019 BTS guideline 1 acknowledges that spontaneous P. aeruginosa clearance can occur, as some patients only culture it intermittently. This contributes to uncertainty about the true benefit of eradication therapy versus natural history.

Evidence Limitations

The 2025 ERS guideline 2 explicitly states the conditional nature of this recommendation reflects:

• Very low certainty of evidence (no RCTs comparing eradication vs. no treatment)
• Unknown rate of spontaneous clearance
• Only 40% achieving eradication with current treatments
• Treatment burden and antimicrobial resistance concerns

Antibiotic Resistance

While there's concern about inducing resistance, one case report 5 interestingly showed P. aeruginosa regaining quinolone susceptibility after 1 year of nebulized tobramycin, though this is anecdotal.

Practical Implementation

The regimen choice depends on:

• Clinical status (stable vs. deteriorating) - deteriorating patients should receive more aggressive second-line therapy 1
• Patient tolerance and preference
• Local antibiotic resistance patterns
• Access to nebulized antibiotics

The evidence strongly supports attempting eradication given the severe consequences of chronic P. aeruginosa infection (increased mortality, frequent exacerbations, hospitalizations, reduced quality of life) 2, even though success rates are modest and evidence quality is limited.